Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

USV Pvt. Ltd. has introduced OnArni, a fixed dose combination of Sacubitril and Valsartan, for the management of Heart ...

USV introduces OnArni, a cost-effective heart failure medication at ₹8 per tablet, improving adherence and health outcomes.

Implantable cardioverter-defibrillators were no better than amiodarone for survival in chronic Chagas cardiomyopathy, though ...

Indian Biotechnology firm Biocon has received approval of its ANDA for Sacubitril/Valsartan Tablets from the US Food and Drug ...

Experts And Viewpoints, May 20, 2021 ACC 2021 PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan Sacubitril valsartan (Entresto), deemed 'the Big E' by some clinicians, has fallen ...

For more information, please contact Andrea at andrealdavis@uabmc.edu or 205-206-9434. Help us find out by joining our study at UAB You may be eligible to participate in the PRECISION-BP research ...

Transportation services are also available upon request. If interested, please email sspaulding@uabmc.edu. You may be eligible to participate in a research study looking at the effects of ...